Foretinib (XL880) | MET/VEGFR2/KDR Inhibitor

Size	Price	US Stock	Global Stock	In Stock
1mg	łÇÍ¶ÊÊ	Inquiry	Inquiry
5mg	łËď¶ÊÊ	Inquiry	Inquiry
100mg	łÇď§¶ÊÊ	Inquiry	Inquiry
250mg	łËîÍ¶ÊÊ	Inquiry	Inquiry
1g	łóďÇ¶ÊÊ	Inquiry	Inquiry

CAS No. :	849217-64-7
Formula :	C₃₄H₃₄F₂N₄O₆
M.W :	632.65
SMILES Code :	O=C(NC1=CC=C(F)C=C1)C2(C(=O)NC3=CC=C(OC=4C=CN=C5C=C(OCCCN6CCOCC6)C(OC)=CC54)C(F)=C3)CC2
Synonyms :	XL880; GSK1363089; EXEL-2880
MDL No. :	MFCD16038048
InChI Key :	CXQHYVUVSFXTMY-UHFFFAOYSA-N
Pubchem ID :	42642645

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302
Precautionary Statements:	P280-P305+P351+P338

ccRCC organoids	10 μM	72 h	To evaluate the effect of Foretinib on ccRCC organoids, results showed that Foretinib consistently induced Cleaved-Caspase 3 activation, indicating apoptosis induction	PMC6393468
MDA-MB-231 cells	1 μM	18 h	To evaluate the effect of Foretinib in combination with PARP inhibitors on DNA damage in MDA-MB-231 cells, showing that the combination significantly increased γ-H2AX foci formation.	PMC4754671
MCF7A02	1 μM	6 days	To validate the synthetic lethality of Foretinib in E-cadherin defective cells, results showed that E-cadherin defective cells were more sensitive to Foretinib.	PMC6296442
MCF10A CDH1-/-	1 μM	6 days	To validate the synthetic lethality of Foretinib in E-cadherin defective cells, results showed that E-cadherin defective cells were more sensitive to Foretinib.	PMC6296442
MV4-11	0.16 nM	48 h	Inhibited the growth of FLT3-ITD mutant cells	PMC10940854
MOLM13	0.89 nM	48 h	Inhibited the growth of FLT3-ITD mutant cells	PMC10940854
HCC1937	1 μM	5 days	To test the effect of Foretinib in combination with afatinib, results showed that the combination treatment significantly inhibited cell growth.	PMC6987485
HDQP1	1 μM	5 days	To test the effect of Foretinib in combination with afatinib, results showed that the combination treatment significantly inhibited cell growth.	PMC6987485
ES2 OVCA cells	100 nM	72 h	To evaluate the effect of M2-M conditioned medium on trametinib cytotoxicity, results showed that M2-M conditioned medium significantly increased the half-lethal concentration of trametinib	PMC7244320
CT26 cells	100 nM	72 h	To evaluate the effect of M2-M conditioned medium on trametinib cytotoxicity, results showed that M2-M conditioned medium significantly increased the half-lethal concentration of trametinib	PMC7244320
MKN-45	10 nM, 100 nM, 1 μM	72 h	Evaluate the effect of Foretinib on the viability of MKN-45 cells, showing reductions in cell viability of 5.4%, 73.7%, and 85.3% at concentrations of 10 nM, 100 nM, and 1 μM, respectively.	PMC8178268
KATO-III	10 nM, 100 nM, 1 μM	72 h	Evaluate the effect of Foretinib on the viability of KATO-III cells, showing reductions in cell viability of 1.2%, 51%, and 78.5% at concentrations of 10 nM, 100 nM, and 1 μM, respectively.	PMC8178268
SNU-1	1 nM, 10 nM, 100 nM, 1 μM	72 h	Evaluate the effect of Foretinib on the viability of SNU-1 cells, showing no significant inhibitory effect at 1 nM, 10 nM, or 100 nM, but a 68.1% reduction in cell viability at 1 μM concentration.	PMC8178268
sympathetic neurons	500 nM	16 h	Foretinib almost completely rescued neurons from degeneration	PMC5674898
sensory neurons	500 nM	48 h	Foretinib rescued sensory neurons from degeneration	PMC5674898
motor neurons	500 nM	9 days	Foretinib significantly promoted the survival of motor neurons	PMC5674898

Nude mice	MDA-MB-231 xenograft model	Oral	5 mg/kg	5 times per week for 26 days	To evaluate the effect of Foretinib in combination with PARP inhibitors on tumor growth in MDA-MB-231 xenograft models, showing that the combination significantly inhibited tumor growth.	PMC4754671
mice	K14cre;Cdh1F/F;Trp53F/F (KEP) model	oral	25 mg/kg or 50 mg/kg	every other day for 28 days	To evaluate the anti-tumour effects of Foretinib in E-cadherin defective tumours, results showed that Foretinib significantly inhibited tumour growth and extended mouse survival.	PMC6296442
Mice	FLT3-ITD AML mouse model	Oral	15 mg/kg	Once daily for 14 days	Foretinib significantly extended the survival of FLT3-ITD AML mice	PMC10940854
nu/nu mice	ES2 xenograft model	tail vein injection	10 mg/kg	every 4 days, until the experimental end point	To evaluate the effect of NanoFore combined with trametinib on tumor progression, results showed that the combination therapy significantly extended the survival of mice	PMC7244320
Mouse	Medulloblastoma model	Continuous osmotic pump infusion into the cerebrospinal fluid	6 mg/kg	28 days, 0.25 μl per hour	To study the anti-tumor effects and resistance mechanisms of Foretinib in a medulloblastoma model	PMC6307130
NOD/SCID mice	subcutaneous and peritoneal dissemination xenograft models	intraperitoneal injection	30 mg/kg	3 times per week for 2 weeks	Evaluate the antitumor effects of Foretinib in gastric cancer models, showing that Foretinib monotherapy significantly inhibited tumor growth and exhibited additive effects when combined with nanoparticle paclitaxel.	PMC8178268
mice	sciatic nerve crush model	oral	100 mg/kg	4 times over 4 days	Foretinib delayed Wallerian degeneration after sciatic nerve crush	PMC5674898

Foretinib

CAS No.: 849217-64-7

Alternative Products

Product Details of Foretinib

Safety of Foretinib

Related Pathways of Foretinib

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT01068587	Lung Cancer	Phase 1 Phase 2	Completed	-	Canada, British Columbia ... More >> BCCA - Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada, L8V 5C2 Ottawa Health Research Institute - General Division Ottawa, Ontario, Canada, K1H 8L6 Univ. Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Less <<
NCT00725712	Neoplasms, Gastrointestinal Tr... More >>act Less <<	Phase 2	Completed	-	United States, Alabama ... More >> GSK Investigational Site Birmingham, Alabama, United States, 35294 United States, Arizona GSK Investigational Site Scottsdale, Arizona, United States, 85258 United States, California GSK Investigational Site Los Angeles, California, United States, 90024 GSK Investigational Site Stanford, California, United States, 94305 United States, District of Columbia GSK Investigational Site Washington, D.C., District of Columbia, United States, 20007 United States, Georgia GSK Investigational Site Atlanta, Georgia, United States, 30309 United States, Illinois GSK Investigational Site Chicago, Illinois, United States, 60637 United States, Massachusetts GSK Investigational Site Boston, Massachusetts, United States, 02114 United States, Michigan GSK Investigational Site Detroit, Michigan, United States, 48201 United States, Montana GSK Investigational Site Billings, Montana, United States, 59101 United States, New Mexico GSK Investigational Site Albuquerque, New Mexico, United States, 87131 United States, New York GSK Investigational Site New York, New York, United States, 10016 GSK Investigational Site New York, New York, United States, 10021 United States, North Carolina GSK Investigational Site Durham, North Carolina, United States, 27710 United States, Oregon GSK Investigational Site Portland, Oregon, United States, 97239 United States, Texas GSK Investigational Site Austin, Texas, United States, 78705 United States, Wisconsin GSK Investigational Site Madison, Wisconsin, United States, 53792 Less <<
NCT00725712	-		Completed	-	-
NCT00726323	Carcinoma, Renal Cell	Phase 2	Completed	-	United States, California ... More >> GSK Investigational Site Greenbrae, California, United States, 94904-2007 GSK Investigational Site San Francisco, California, United States, 94115 GSK Investigational Site Stanford, California, United States, 94305 United States, Indiana GSK Investigational Site Indianapolis, Indiana, United States, 46202 United States, Maryland GSK Investigational Site Bethesda, Maryland, United States, 20892 United States, Massachusetts GSK Investigational Site Boston, Massachusetts, United States, 02115 United States, Michigan GSK Investigational Site Detroit, Michigan, United States, 48201 United States, New Jersey GSK Investigational Site New Brunswick, New Jersey, United States, 08901 United States, Ohio GSK Investigational Site Cleveland, Ohio, United States, 44195 United States, Pennsylvania GSK Investigational Site Philadelphia, Pennsylvania, United States, 19104 United States, Tennessee GSK Investigational Site Nashville, Tennessee, United States, 37232 United States, Texas GSK Investigational Site San Antonio, Texas, United States, 78229 Less <<
NCT00725764	Neoplasms, Head and Neck	Phase 2	Completed	-	United States, Georgia ... More >> GSK Investigational Site Atlanta, Georgia, United States, 30309 United States, Illinois GSK Investigational Site Chicago, Illinois, United States, 60637 United States, Indiana GSK Investigational Site Indianapolis, Indiana, United States, 46254 United States, Minnesota GSK Investigational Site Minneapolis, Minnesota, United States, 55407-3799 United States, Missouri GSK Investigational Site Saint Louis, Missouri, United States, 63110 United States, New Hampshire GSK Investigational Site Lebanon, New Hampshire, United States, 03756 United States, South Carolina GSK Investigational Site Charleston, South Carolina, United States, 29403 United States, Tennessee GSK Investigational Site Nashville, Tennessee, United States, 37203 United States, Texas GSK Investigational Site Houston, Texas, United States, 77030 GSK Investigational Site San Antonio, Texas, United States, 78229 United States, West Virginia GSK Investigational Site Morgantown, West Virginia, United States, 28506 Less <<
NCT00743067	Solid Tumours	Phase 1	Completed	-	-
NCT00742131	Solid Tumours	PHASE1	COMPLETED	2011-08-29	-
NCT02034097	Cancer	Phase 2	Withdrawn(GSK has decided to t... More >>erminate the Product Development of foretinib and conclude our Development Agreement with Exelixis) Less <<	December 2016	-
NCT01147484	Recurrent Breast Cancer	PHASE2	COMPLETED	2015-02-13	Tom Baker Cancer Centre, Calga... More >>ry, Alberta, T2N 4N2, Canada\|BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, V1Y 5L3, Canada\|BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, V5Z 4E6, Canada\|QEII Health Sciences Centre, Halifax, Nova Scotia, B3H 1V7, Canada\|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, L8V 5C2, Canada\|London Regional Cancer Program, London, Ontario, N6A 4L6, Canada\|Ottawa Health Research Institute - General Division, Ottawa, Ontario, K1H 8L6, Canada\|Hopital Charles LeMoyne, Greenfield Park, Quebec, J4V 2H1, Canada\|Allan Blair Cancer Centre, Regina, Saskatchewan, S4T 7T1, Canada Less <<
NCT01138384	Breast Cancer	Phase 1 Phase 2	Completed	-	Canada, British Columbia ... More >> BCCA - Cancer Centre for the Southern Interior Kelowna, British Columbia, Canada, V1Y 5L3 BCCA - Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Cancer Centre of Southeastern Ontario at Kingston Kingston, Ontario, Canada, K7L 5P9 London Regional Cancer Program London, Ontario, Canada, N6A 4L6 Canada, Quebec McGill University - Dept. Oncology Montreal, Quebec, Canada, H2W 1S6 Less <<
NCT00726323	-		Completed	-	-
NCT00725764	-		Completed	-	-
NCT00920192	Carcinoma, Hepatocellular	PHASE1	COMPLETED	2015-03-24	GSK Investigational Site, Hong... More >> Kong, Hong Kong\|GSK Investigational Site, Tainan, 70428, Taiwan\|GSK Investigational Site, Taipei, 110, Taiwan\|GSK Investigational Site, Taipei, 112, Taiwan\|GSK Investigational Site, Bangkok, 10400, Thailand\|GSK Investigational Site, Bangkok, 10700, Thailand\|GSK Investigational Site, Khon Kaen, 40002, Thailand Less <<
NCT00742261	Solid Tumours	PHASE1	COMPLETED	2009-06-24	GSK Investigational Site, Detr... More >>oit, Michigan, 48201, United States\|GSK Investigational Site, Houston, Texas, 77030-4009, United States Less <<

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	1.58mL 0.32mL 0.16mL	7.90mL 1.58mL 0.79mL	15.81mL 3.16mL 1.58mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed